News & Events

January 2019

January 8, 2019 FUJIFILM Cellular Dynamics Inc. Launches New Product iCell Microglia, an iPSC-Derived Neural Cell TypeDownload PDF

hiPSC-derived microglia are utilized with the aim of advancing research to fulfill unmet medical needs for patients with neurodegenerative diseases

 MADISON, Wis., January 08, 2019 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and tissue-specific cells differentiated  from iPSCs, has announced the launch of its newest product, iCell® Microglia. Microglia are the immune cells of the central nervous system responsible for fundamental physiological and pathological processes. Differentiated from human iPSCs, iCell Microglia will be used in life science research to enable the study and development of therapies for degenerative neurological diseases such as Alzheimer’s disease…

January 3, 2019 FUJIFILM Cellular Dynamics to Establish New Facility for Production of Human iPS Cell Therapy ApplicationsDownload PDF

Fujifilm is investing in the cGMP-compliant facility located in Madison, Wisconsin with the goal to begin operations by March 2020

MADISON, Wis., January 3, 2019 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a US subsidiary of FUJIFILM Corporation (President: Kenji Sukeno) and a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, has announced an investment of about $21 million to open a new cGMP-compliant  production facility with the goal of industrializing iPS cell manufacturing for regenerative medicine therapies. The facility will support FCDI’s internal cell therapeutics pipeline and will also serve as a Contract Development and Manufacturing Organization (CDMO) for iPS cell products.